Johnson & Johnson (JNJ) and AbbVie (ABBV) are two prominent Dividend Kings, each boasting a long history of annual dividend increases. JNJ stands out with its diversified healthcare portfolio spanning pharmaceuticals and medical devices, which positions it well against competition and patent expirations. The company anticipates reaching $100 billion in revenue by 2026, bolstered by a robust product pipeline and a AAA credit rating, making it an attractive option for risk-averse investors.
In contrast, AbbVie has seen impressive growth driven by its immunology products, Skyrizi and Rinvoq, contributing significantly to a 12.4% year-over-year revenue increase in Q1. Despite its narrower focus, AbbVie is not facing major patent cliffs in the near term and has potential growth from new product launches. However, its reliance on a couple of key drugs raises some risk.
For investors prioritizing stability, Johnson & Johnson appears to be the safer choice due to its extensive product range and consistent dividend history, while AbbVie may offer higher growth potential if its key products continue to perform well.
Source: fool.com